Kos Announces Annual Shareholders Meeting April 27, 2006

About Kos

Kos Pharmaceuticals, Inc. is a fully integrated specialtypharmaceutical company engaged in developing, commercializing,manufacturing and marketing proprietary prescription products for thetreatment of chronic diseases with a particular focus on thecardiovascular, metabolic and respiratory disease areas. The Company'sprincipal product development strategy is to reformulate existingpharmaceutical products with large market potential to improve safety,efficacy, and patient compliance. Kos' strategy also includes makingmeasured investments in new chemical entity research through in-houseand sponsored research, scientific in-licensing and general corporatedevelopment activities. The Company currently markets Niaspan(R) andAdvicor(R) for the treatment of cholesterol disorders, Azmacort(R) forthe treatment of asthma, Cardizem(R)LA for the treatment ofhypertension and angina, and Teveten(R) and Teveten(R)HCT for thetreatment of hypertension. Kos has a strong and growing research anddevelopment pipeline including proprietary drug delivery technologiesin solid-dose, inhalation and aerosol metered-dose deviceadministration to help fuel sustained, organic sales growth into thefuture.

Certain statements in this press release, including statementsrelating to the Company's strong and growing research and developmentpipeline and future sales growth are forward-looking and are subjectto risks and uncertainties which may cause actual results to differmaterially from those projected in a forward-looking statement. Theserisks and uncertainties include, the Company's ability to attract andretain sales professionals and increase the size of its sales force,the Company's ability to successfully develop (both internally andthrough sponsored research arrangements with third parties) andcommercialize new products under development and within expectedtimeframes, the Company's ability to successfully negotiate additionalimportant strategic business development and corporate opportunities,the progress of the Company's research and development pipeline, theprotection afforded by the Company's patents and those related to theacquired and licensed products, the effect of conditions in thepharmaceutical industry and the economy in general, the Company'sability to maintain compliance with FDA standards without adverselyaffecting its manufacturing capability or ability to meet itsproduction requirements, the Company's ability to ensure compliancewith prescription drug sales and marketing laws and regulations,changes in the regulatory environment governing the Company'scompliance with FDA. A more detailed discussion of risks attendant tothe forward-looking statements included in this press release are setforth in the "Forward-Looking Information: Certain CautionaryStatements" section of the Company's Annual Report on Form 10-K forthe year ended December 31, 2005, filed with the Securities andExchange Commission, and in other reports filed with the SEC.